ArticleEuropean journal of medical research2025
The prognostic value of calcium channel blockers usage for overall survival and recurrence-free survival in patients with endometrial cancer.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo evaluate the prognosis for endometrial cancer (EC) patients who used calcium channel blockers (CCB) with hypertension and its predictive function.
methodsPatients diagnosed with EC who underwent surgery at our hospital between January 2014 and December 2023 were enrolled and divided into a training set and a validation set at a 2:1 ratio. Clinical characteristics and medical information were extracted from patient records. Predictive factors were assessed using univariate and multivariate analyses in the training set. ROC and DCA were employed to evaluate the predictive value of CCB in both the training and validation sets. Survival analysis was conducted to investigate function of antihypertensive drugs and calcium level.
resultsIn the training set, univariate analysis showed that age, CA125, CCB use, tumor grade, FIGO stage, histological type, peritoneal cytology, lymph node metastasis, and lymph-vascular space invasion (LVSI) were significantly associated with overall survival (OS) and recurrence-free survival (RFS; all P < 0.05). After adjusting for confounders, CCB use remained independently predictive of improved OS (Model I: HR = 0.1, 95% CI: 0.0-0.4, P < 0.001; Model II: HR = 0.2, 95% CI: 0.1-0.5, P = 0.006) and RFS (Model I: HR = 0.2, 95% CI: 0.1-0.5, P < 0.001; Model II: HR = 0.2, 95% CI: 0.1-0.7, P = 0.009). Both CCB and calcium ion levels have significant impacts on the long-term survival of patients with hypertension. ROC and DCA demonstrated that incorporating CCB use significantly enhanced diagnostic accuracy for OS and RFS in both the training and validation sets. Survival analyses further supported these findings.
conclusionThis study suggests that hypertensive EC patients using CCB exhibit significantly improved OS and RFS prediction accuracy, with consistent results across training and validation cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.